Clinical Cancer Research, volume 25, issue 1, pages 177-187
Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer
Kularatne Sumith A
1
,
Thomas Mini
1
,
Myers Carrie H
1
,
Gagare Pravin
1
,
Kanduluru Ananda Kumar
1
,
Crian Christa J
2
,
Cichocki Brandy N
2
1
1On Target Laboratories, West Lafayette, Indiana.
|
2
2Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana.
|
Publication type: Journal Article
Publication date: 2018-09-10
Journal:
Clinical Cancer Research
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor: 11.5
ISSN: 10780432, 15573265
Cancer Research
Oncology
Abstract
Purpose:
The ability to locate and remove all malignant lesions during radical prostatectomy leads not only to prevent biochemical recurrence (BCR) and possible side effects but also to improve the life expectancy of patients with prostate cancer. Fluorescence-guided surgery (FGS) has emerged as a technique that uses fluorescence to highlight cancerous cells and guide surgeons to resect tumors in real time. Thus, development of tumor-specific near-infrared (NIR) agents that target biomarkers solely expressed on prostate cancer cells will enable to assess negative tumor margins and affected lymph nodes.
Experimental Design:
Because PSMA is overexpressed in prostate cancer cells in >90% of the prostate cancer patient population, a prostate-specific membrane antigen (PSMA)-targeted NIR agent (OTL78) was designed and synthesized. Optical properties, in vitro and in vivo specificity, tumor-to-background ratio (TBR), accomplishment of negative surgical tumor margins using FGS, pharmacokinetics (PKs) properties, and preclinical toxicology of OTL78 were then evaluated in requisite models.
Results:
OTL78 binds to PSMA-expressing cells with high affinity, concentrates selectively to PSMA-positive cancer tissues, and clears rapidly from healthy tissues with a half-time of 17 minutes. It also exhibits an excellent TBR (5:1) as well as safety profile in animals.
Conclusions:
OTL78 is an excellent tumor-specific NIR agent for use in fluorescence-guided radical prostatectomy and FGS of other cancers.
Citations by journals
|
1
2
3
|
|
|
Small
|
Small
3 publications, 6.12%
|
|
Journal of Nuclear Medicine
|
Journal of Nuclear Medicine
2 publications, 4.08%
|
|
Frontiers in Oncology
|
Frontiers in Oncology
2 publications, 4.08%
|
|
Sensors and Actuators, B: Chemical
|
Sensors and Actuators, B: Chemical
2 publications, 4.08%
|
|
The Lancet Oncology
|
The Lancet Oncology
2 publications, 4.08%
|
|
Advanced healthcare materials
|
Advanced healthcare materials
2 publications, 4.08%
|
|
Journal of Medicinal Chemistry
|
Journal of Medicinal Chemistry
1 publication, 2.04%
|
|
Medicinal Chemistry Research
|
Medicinal Chemistry Research
1 publication, 2.04%
|
|
Molecules
|
Molecules
1 publication, 2.04%
|
|
Journal of Biomedical Optics
|
Journal of Biomedical Optics
1 publication, 2.04%
|
|
Cancers
|
Cancers
1 publication, 2.04%
|
|
Biomolecules
|
Biomolecules
1 publication, 2.04%
|
|
Frontiers in Pharmacology
|
Frontiers in Pharmacology
1 publication, 2.04%
|
|
International Journal of Molecular Sciences
|
International Journal of Molecular Sciences
1 publication, 2.04%
|
|
Prostate Cancer and Prostatic Diseases
|
Prostate Cancer and Prostatic Diseases
1 publication, 2.04%
|
|
Nature Reviews Clinical Oncology
|
Nature Reviews Clinical Oncology
1 publication, 2.04%
|
|
International Urology and Nephrology
|
International Urology and Nephrology
1 publication, 2.04%
|
|
Molecular Imaging and Biology
|
Molecular Imaging and Biology
1 publication, 2.04%
|
|
Chemical Engineering Journal
|
Chemical Engineering Journal
1 publication, 2.04%
|
|
Heliyon
|
Heliyon
1 publication, 2.04%
|
|
European Urology Focus
|
European Urology Focus
1 publication, 2.04%
|
|
Clinical Genitourinary Cancer
|
Clinical Genitourinary Cancer
1 publication, 2.04%
|
|
Physics Letters, Section A: General, Atomic and Solid State Physics
|
Physics Letters, Section A: General, Atomic and Solid State Physics
1 publication, 2.04%
|
|
Small Structures
|
Small Structures
1 publication, 2.04%
|
|
Bioconjugate Chemistry
|
Bioconjugate Chemistry
1 publication, 2.04%
|
|
ACS Chemical Biology
|
ACS Chemical Biology
1 publication, 2.04%
|
|
ACS Biomaterials Science and Engineering
|
ACS Biomaterials Science and Engineering
1 publication, 2.04%
|
|
Chemical Society Reviews
|
Chemical Society Reviews
1 publication, 2.04%
|
|
International Journal of Nanomedicine
|
International Journal of Nanomedicine
1 publication, 2.04%
|
|
1
2
3
|
Citations by publishers
|
2
4
6
8
10
12
|
|
|
Elsevier
|
Elsevier
11 publications, 22.45%
|
|
Wiley
|
Wiley
11 publications, 22.45%
|
|
Springer Nature
|
Springer Nature
6 publications, 12.24%
|
|
American Chemical Society (ACS)
|
American Chemical Society (ACS)
5 publications, 10.2%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
4 publications, 8.16%
|
|
Frontiers Media S.A.
|
Frontiers Media S.A.
3 publications, 6.12%
|
|
Society of Nuclear Medicine and Molecular Imaging
|
Society of Nuclear Medicine and Molecular Imaging
2 publications, 4.08%
|
|
SPIE
|
SPIE
1 publication, 2.04%
|
|
Royal Society of Chemistry (RSC)
|
Royal Society of Chemistry (RSC)
1 publication, 2.04%
|
|
Dove Medical Press
|
Dove Medical Press
1 publication, 2.04%
|
|
American Association for Cancer Research (AACR)
|
American Association for Cancer Research (AACR)
1 publication, 2.04%
|
|
Pleiades Publishing
|
Pleiades Publishing
1 publication, 2.04%
|
|
2
4
6
8
10
12
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2018,2019,2020,2021,2022,2023,2024],"ids":[0,0,0,0,0,0,0],"codes":[0,0,0,0,0,0,0],"imageUrls":["","","","","","",""],"datasets":[{"label":"Citations number","data":[1,6,6,10,13,12,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["2.04","12.24","12.24","20.41","26.53","24.49","2.04"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Small","Journal of Nuclear Medicine","Frontiers in Oncology","Sensors and Actuators, B: Chemical","The Lancet Oncology","Advanced healthcare materials","Journal of Medicinal Chemistry","Medicinal Chemistry Research","Molecules","Journal of Biomedical Optics","Cancers","Biomolecules","Frontiers in Pharmacology","International Journal of Molecular Sciences","Prostate Cancer and Prostatic Diseases","Nature Reviews Clinical Oncology","International Urology and Nephrology","Molecular Imaging and Biology","Chemical Engineering Journal","Heliyon","European Urology Focus","Clinical Genitourinary Cancer","Physics Letters, Section A: General, Atomic and Solid State Physics","Small Structures","Bioconjugate Chemistry","ACS Chemical Biology","ACS Biomaterials Science and Engineering","Chemical Society Reviews","International Journal of Nanomedicine"],"ids":[9872,3170,10990,22419,511,21975,3673,6106,1770,11544,22471,13780,9788,14627,3280,6763,12895,8168,16275,21848,7899,6147,2947,27248,4795,2045,19167,20586,10956],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/lptvolCQExQDfYMEFUltdCPdFYmoPWhMIl0NeZBP_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/DBpVkewJngs3BK2gVqHayOcCZf2Czbxddw6ObU26_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/leiAYcRDGTSl5B1eCnwpSGqmDEUEfDPPoYisFGhT_medium.webp","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp"],"datasets":[{"label":"","data":[3,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[6.12,4.08,4.08,4.08,4.08,4.08,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04,2.04],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Elsevier","Wiley","Springer Nature","American Chemical Society (ACS)","Multidisciplinary Digital Publishing Institute (MDPI)","Frontiers Media S.A.","Society of Nuclear Medicine and Molecular Imaging","SPIE","Royal Society of Chemistry (RSC)","Dove Medical Press","American Association for Cancer Research (AACR)","Pleiades Publishing"],"ids":[17,11,8,40,202,208,1153,7162,123,417,2286,101],"codes":[0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/lptvolCQExQDfYMEFUltdCPdFYmoPWhMIl0NeZBP_medium.webp","\/storage\/images\/resized\/DBpVkewJngs3BK2gVqHayOcCZf2Czbxddw6ObU26_medium.webp","\/storage\/images\/resized\/leiAYcRDGTSl5B1eCnwpSGqmDEUEfDPPoYisFGhT_medium.webp","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp","\/storage\/images\/resized\/cfuVw6XIq2mATDNJdXiose3W8qYbkmaVSpHoP8XL_medium.webp","\/storage\/images\/resized\/oZgeErrVFhuDksyqFURLvYS1wtVSBWczh001igGo_medium.webp"],"datasets":[{"label":"","data":[11,11,6,5,4,3,2,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[22.45,22.45,12.24,10.2,8.16,6.12,4.08,2.04,2.04,2.04,2.04,2.04],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Metrics
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Kularatne S. A. et al. Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer // Clinical Cancer Research. 2018. Vol. 25. No. 1. pp. 177-187.
GOST all authors (up to 50)
Copy
Kularatne S. A., Thomas M., Myers C. H., Gagare P., Kanduluru A. K., Crian C. J., Cichocki B. N. Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer // Clinical Cancer Research. 2018. Vol. 25. No. 1. pp. 177-187.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1158/1078-0432.CCR-18-0803
UR - https://doi.org/10.1158%2F1078-0432.CCR-18-0803
TI - Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer
T2 - Clinical Cancer Research
AU - Kularatne, Sumith A
AU - Thomas, Mini
AU - Myers, Carrie H
AU - Gagare, Pravin
AU - Kanduluru, Ananda Kumar
AU - Crian, Christa J
AU - Cichocki, Brandy N
PY - 2018
DA - 2018/09/10 00:00:00
PB - American Association for Cancer Research (AACR)
SP - 177-187
IS - 1
VL - 25
SN - 1078-0432
SN - 1557-3265
ER -
Cite this
BibTex
Copy
@article{2018_Kularatne,
author = {Sumith A Kularatne and Mini Thomas and Carrie H Myers and Pravin Gagare and Ananda Kumar Kanduluru and Christa J Crian and Brandy N Cichocki},
title = {Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer},
journal = {Clinical Cancer Research},
year = {2018},
volume = {25},
publisher = {American Association for Cancer Research (AACR)},
month = {sep},
url = {https://doi.org/10.1158%2F1078-0432.CCR-18-0803},
number = {1},
pages = {177--187},
doi = {10.1158/1078-0432.CCR-18-0803}
}
Cite this
MLA
Copy
Kularatne, Sumith A., et al. “Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer.” Clinical Cancer Research, vol. 25, no. 1, Sep. 2018, pp. 177-187. https://doi.org/10.1158%2F1078-0432.CCR-18-0803.